BRM

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

Retrieved on: 
Tuesday, April 9, 2024
Well, BRM, Acetyltransferase, Gene expression, Survival, NSCLC, PD, SMARCA2, Neoplasm, Megakaryocyte, Cancer, Prostate, Lung cancer, Protein, IND, EP300, AACR, ATPase, Therapy, BRG1, Safety, CBP, Lilly, Anemia, ID, Thrombocytopenia, Annual general meeting, Pharmaceutical industry

CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced new preclinical data for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, selective CBP degrader, and selective EP300 degrader programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting. Foghorn management will hold a conference call and webcast today at 5 p.m. ET to review important pipeline updates.

Key Points: 
  • “Notably, our first-in-class BRM selective inhibitor FHD-909 has demonstrated favorable tolerability and encouraging dose-dependent single agent activity in preclinical models of BRG1 mutated tumors.
  • Additionally, we are applying our long-acting formulation capabilities to our degrader programs, which further enhances the clinical potential of these drug candidates.
  • However, the ATPase domains of BRM and BRG1are 92% identical which has made identifying a selective BRM inhibitor challenging.
  • Attempts to selectively inhibit CBP or EP300 individually have been challenging due to the high homology between the two proteins.

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

Retrieved on: 
Tuesday, March 26, 2024
BRM, CBP, Foghorn, Webcast, SMARCA2, EP300, AACR, Conference, Conference call, Acute leukemia, Gene expression, AML, Pharmaceutical industry

CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- March 26, 2024 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced plans to host a conference call and webcast on April 9th at 5 p.m. ET / 2 p.m. PT. Foghorn management will review key programs in its pipeline, including FHD-286 for acute myelogenous leukemia (AML), and new preclinical data being presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, and for the selective CBP and selective EP300 degrader programs.

Key Points: 
  • Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader programs
    Conference call and webcast on April 9th at 5 p.m.
  • ET / 2 p.m. PT
    CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- March 26, 2024 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced plans to host a conference call and webcast on April 9th at 5 p.m.
  • ET / 2 p.m. PT.
  • Foghorn management will review key programs in its pipeline, including FHD-286 for acute myelogenous leukemia (AML), and new preclinical data being presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, and for the selective CBP and selective EP300 degrader programs.

Cybersecurity CEOs join forces to launch Lockchain.ai: The First AI-Powered Blockchain Risk Management Platform

Retrieved on: 
Monday, April 1, 2024
Bitcoin, Kraken, BRM, Automation, Software as a service, Risk management, ARCA, Intelligence, Cause of action, Barracuda Networks, Blockchain, Harvard Business School, AI, Investment, Pain, Cryptocurrency

ATHENS, Ga., April 1, 2024 /PRNewswire/ --  Lockchain.ai, the AI-powered Blockchain Risk Management platform, has announced its official launch from stealth to bring automated risk management solutions to traders, investors, and fund managers in the blockchain ecosystem. Lockchain.ai, founded by two experienced cybersecurity CEOs, Aidan Kehoe and Andrew Howard, as well as Matt Higgins, with seed funding led by Lerer Hippeau, leverages generative AI to bring speed, scalability, transparency, and security to the rapidly evolving business of digital asset management - key capabilities in avoiding future black swan events.

Key Points: 
  • ATHENS, Ga., April 1, 2024 /PRNewswire/ -- Lockchain.ai , the AI-powered Blockchain Risk Management platform, has announced its official launch from stealth to bring automated risk management solutions to traders, investors, and fund managers in the blockchain ecosystem.
  • Lockchain.ai's SaaS platform provides always-on due diligence and risk monitoring for asset managers and traders seeking real-time security status of the assets they trade.
  • "All responsible financial services firms that want to engage with digital assets need a robust risk management process," explained Jan van Eck, CEO of VanEck Associates.
  • Lockchain helps process a wealth of relevant and useful data and provides insights to risk management professionals, whether they are technical experts or not."

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

Retrieved on: 
Thursday, March 7, 2024
EP300, NSCLC, Merck, Research, AML, Neoplasm, ARID1B, Investment, CBP, Cancer, Prostate, AACR, Factorization of polynomials, Lung cancer, Safety, MDS, Collaboration, Gene expression, Thrombocytopenia, Lilly, Medicine, Patient, Survival, IND, LDAC, Development, Colorectal cancer, BRM, Chromatin, Prostate cancer, Pharmaceutical industry

“In 2023 we initiated a combination study with FHD-286 in AML, with data anticipated in the second half of 2024.

Key Points: 
  • “In 2023 we initiated a combination study with FHD-286 in AML, with data anticipated in the second half of 2024.
  • The IND is planned for the second quarter of 2024, with an initial focus in non-small cell lung cancer.
  • The Company is conducting preclinical work to further explore the opportunity and expects data in the second quarter of 2024.
  • Foghorn is presenting new preclinical data for its CBP and EP300 selective degrader programs at the 2024 AACR Annual Meeting, April 5-10, 2024.

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909

Retrieved on: 
Tuesday, March 5, 2024
EP300, PD, Chemistry, CBP, BRD9, Chromatin, AACR, SMARCA2, Safety, Gene expression, Thrombocytopenia, Lilly, IND, Poster, BRM, Pharmaceutical industry

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that preclinical data for its pipeline programs, including the first presentation of preclinical data for FHD-909, a potential first-in-class BRM (SMARCA2) selective inhibitor will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 in San Diego, California. In addition to the FHD-909 poster, the Company will have a symposium presentation, a town hall talk, and poster presentations on its selective CBP degrader and selective EP300 degrader programs.

Key Points: 
  • In addition to the FHD-909 poster, the Company will have a symposium presentation, a town hall talk, and poster presentations on its selective CBP degrader and selective EP300 degrader programs.
  • “Our 2024 AACR presentations showcase the significant progress that Foghorn has made advancing multiple potential first-in-class medicines, based on our unique capabilities targeting the chromatin regulatory system” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn.
  • In addition, we will present data highlighting our long-acting formulation capabilities that enable up to once-a-month dosing for protein degraders, which we believe meaningfully differentiate our programs and platform.”
    Symposium Session: TM04 – Losing our inhibitions – is (protein) degradation preferred?
  • : A chemistry in Cancer Research Working Group Town Hall Meeting
    Poster Title: Identification of selective CBP degraders with robust preclinical PK, PD, efficacy and safety across solid tumor indications
    Poster Title: Long acting injectable FHD-609 micro-suspension: A potent BRD9 degrader with comparable efficacy, reduced frequency of dosing in preclinical models
    The presentation and the posters will be accessible under the Science section of the Company’s website after the conference.

Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor

Retrieved on: 
Thursday, February 8, 2024
Gene expression, BRM, Lung cancer, Survival, IND, Lilly, Foghorn, NSCLC, Pharmaceutical industry

Selective BRM inhibition has been a sought-after objective in cancer research for many years.

Key Points: 
  • Selective BRM inhibition has been a sought-after objective in cancer research for many years.
  • A variety of tumor types, including NSCLC, are known to have mutations in BRG1, which we believe make them dependent on BRM activity for their survival.
  • Selective blocking of BRM activity is considered a promising strategy for causing tumor cell death while sparing healthy cells.
  • The collaboration includes a US 50/50 co-development and co-commercialization agreement for Foghorn’s Selective BRM oncology program and an additional undisclosed oncology target.

Farm Management Canada’s Annual Agricultural Conference is Sowing the Seeds of Excellence

Retrieved on: 
Friday, January 26, 2024
Risk management, Farm, Learning, Credit, Farmer, Policy, BRM, Real World, Woman, Government, Mental health, Food, MNP, Guilt, Conference, Mississaugas, The Honourable, Organization, Opportunity, United Therapeutics

OTTAWA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Farm Management Canada held its annual Agricultural Excellence (AgEx) Conference in Guelph, Ontario welcoming farm management enthusiasts from across Canada to gather, learn and exchange knowledge and insights!

Key Points: 
  • OTTAWA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Farm Management Canada held its annual Agricultural Excellence (AgEx) Conference in Guelph, Ontario welcoming farm management enthusiasts from across Canada to gather, learn and exchange knowledge and insights!
  • The agenda provided a diverse learning experience for participants, covering a multitude of farm business management topics.
  • During the annual Agricultural Excellence Banquet, Alberta's Steve Funk was recognized for his contribution to farm management excellence with the prestigious Wilson Loree Award.
  • Join Farm Management Canada in Abbotsford-Chilliwack, British Columbia for AgEx 2024 | November 19-21, 2024.

Big Red M Ushers in New Era with KiKi L'Italien as Vice President

Retrieved on: 
Thursday, January 18, 2024
Cvent, Kiki, Knowledge, BRM, Meeting, Woman, Blog, Leadership studies, Human, Marketing, ASAE, Hall, Education, Growth

FALLS CHURCH, Va., Jan. 18, 2024 /PRNewswire/ -- Big Red M (BRM) announced today that it elected KiKi L'Italien as its new vice president of marketing and community engagement, effective January 1, 2024.

Key Points: 
  • FALLS CHURCH, Va., Jan. 18, 2024 /PRNewswire/ -- Big Red M (BRM) announced today that it elected KiKi L'Italien as its new vice president of marketing and community engagement, effective January 1, 2024.
  • "I am delighted for KiKi L'Italien to become the new vice president of marketing and community of Big Red M. As a recognized voice in the association industry through her consulting expertise and highly regarded Association Chat media platform , KiKi has exhibited her extensive industry knowledge, expansive network, and strong leadership.
  • She is the perfect person to take on this new role in our rapidly growing company," said Lucas McCann, CEO.
  • I look forward to working with our dynamic team to continue on a path of further growth," stated L'Italien.

Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024

Retrieved on: 
Monday, January 8, 2024
LDAC, Medicine, IND, Colorectal cancer, EGFR, BRG1, Prostate cancer, Factorization of polynomials, MDS, Thrombocytopenia, Gene expression, Chromatin, Neoplasm, Prostate, CBP, Cancer, Patient, Safety, ARID1B, AML, NSCLC, BRM, EP300, Pharmaceutical industry

This will also include preclinical combination data of FHD-286 with tyrosine kinase inhibitors of EGFR and KRAS.

Key Points: 
  • This will also include preclinical combination data of FHD-286 with tyrosine kinase inhibitors of EGFR and KRAS.
  • Over the next four years, we anticipate the filing of at least six new INDs, reflecting the productivity of our precision medicine platform.
  • This is all supported by our cash and equivalents position of approximately $259.9 million as of September 30, 2023.”
    FHD-286.
  • Foghorn is engaged in a strategic collaboration with Loxo@Lilly and continues to advance the BRM selective inhibitor and degrader programs along with other undisclosed programs.

Hunter Shkolnik, Partner, NSPR Law Services, Appointed Executive Committee for the Self-Funded Payer Track Insulin Pricing Litigation Case No. 2:23-md-03080 (BRM)(RLS) MDL No. 3080

Retrieved on: 
Wednesday, December 20, 2023
Health, Professional Services, Class Action Lawsuit, Pharmaceutical, Legal, NSPR, Executive Committee, School, Self, Local government, Organization, RLS, MDL, BRM, Partner

Hunter Shkolnik , a Partner in NSPR Law Services — widely considered one of the country’s leading personal injury attorneys — has been appointed to the Executive Committee for the Self -Funded Payer Track Insulin Pricing Litigation Case No.

Key Points: 
  • Hunter Shkolnik , a Partner in NSPR Law Services — widely considered one of the country’s leading personal injury attorneys — has been appointed to the Executive Committee for the Self -Funded Payer Track Insulin Pricing Litigation Case No.
  • 2:23-md-03080 (BRM)(RLS) MDL No.
  • 3080, currently in the N.J. courts under the jurisdiction of Judge Brian R. Martinotti and Judge Rukhsana l. Singh.
  • In that role, he will collaborate with a selection of peers on the management of the litigation and leadership structures for Plaintiffs spanning self-funded payers or self-funded payer groups, including local governments and subdivisions (including county, borough, municipality, city, town, township, parish, local public authority, special district, intrastate district, council of governments, and agencies or instrumentalities of multi-regional or intra-state or local government); unions; schools and educational institutions; for-profit and non-profit organizations; and other similar self-funded payers who pay for prescription drugs provided to members of their health plan with prescription drug coverage.